FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3147966162> ?p ?o ?g. }

• W3147966162 abstract "Cancer cells undergo lineage switching during natural progression and in response to therapy. NKX2-1 loss in human and murine lung adenocarcinoma leads to invasive mucinous adenocarcinoma (IMA), a lung cancer subtype that exhibits gastric differentiation and harbors a distinct spectrum of driver oncogenes. In murine BRAFV600E-driven lung adenocarcinoma, NKX2-1 is required for early tumorigenesis, but dispensable for established tumor growth. NKX2-1-deficient, BRAFV600E-driven tumors resemble human IMA and exhibit a distinct response to BRAF/MEK inhibitors. Whereas BRAF/MEK inhibitors drive NKX2-1-positive tumor cells into quiescence, NKX2-1-negative cells fail to exit the cell cycle after the same therapy. BRAF/MEK inhibitors induce cell identity switching in NKX2-1-negative lung tumors within the gastric lineage, which is driven in part by WNT signaling and FoxA1/2. These data elucidate a complex, reciprocal relationship between lineage specifiers and oncogenic signaling pathways in the regulation of lung adenocarcinoma identity that is likely to impact lineage-specific therapeutic strategies.When cells become cancerous they grow uncontrollably and spread into surrounding healthy tissue. As the cancer progresses different genes are switched on and off which can cause tumor cells to change their identity and transition into other types of cell. How closely tumor cells resemble the healthy tissue they came from can influence how well the cancer responds to treatment. Many lung cancers have an identity similar to normal lung cells. However, some turn off a gene that codes for a protein called NKX2-1, which leads to a type of cancer called invasive mucinous adenocarcinoma (or IMA for short). Cells from this type of cancer develop an identity similar to mucous cells that line the surface of the stomach. But it was unclear how IMA tumor cells that developed from a mutation in the BRAF gene are affected by this loss in NKX2-1, and how transitioning to a different cell type impacts their response to treatment. To investigate this, Zewdu et al. studied lung cells from patients with IMA tumors driven by a mutation in BRAF and cells from mice that have been genetically engineered to have a similar form of cancer. This revealed that the NKX2-1 protein is needed to initiate the formation of cancer cells but is not required for the growth of already established BRAF-driven tumors. Further experiments showed that removing the gene for NKX2-1 made these cancer cells less responsive to drugs known as BRAF/MEK inhibitors that are commonly used to treat cancer. These drugs caused the IMA cancer cells to change their identity and become another type of stomach cell. This identity change was found to depend on two signaling pathways which cells use to communicate. This study provides some explanation of how IMA lung cancers that lack the gene for NKX2-1 resist treatment with BRAF/MEK inhibitors. It also shows new relationships between key genes in these cancers and systems for cell communication. These findings could lead to better therapies for lung cancer, particularly for patients whose tumor cells are deficient in NKX2-1 and therefore require specialized treatment." @default.
• W3147966162 created "2021-04-13" @default.
• W3147966162 creator A5019518945 @default.
• W3147966162 creator A5021530580 @default.
• W3147966162 creator A5021909111 @default.
• W3147966162 creator A5024050751 @default.
• W3147966162 creator A5042159563 @default.
• W3147966162 creator A5052337435 @default.
• W3147966162 creator A5070881090 @default.
• W3147966162 creator A5074678243 @default.
• W3147966162 creator A5075201122 @default.
• W3147966162 creator A5075271749 @default.
• W3147966162 creator A5082044599 @default.
• W3147966162 date "2021-04-06" @default.
• W3147966162 modified "2023-09-24" @default.
• W3147966162 title "An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma" @default.
• W3147966162 cites W1135931197 @default.
• W3147966162 cites W1631320694 @default.
• W3147966162 cites W1724512254 @default.
• W3147966162 cites W1946402563 @default.
• W3147966162 cites W1965157206 @default.
• W3147966162 cites W1976697496 @default.
• W3147966162 cites W1977731422 @default.
• W3147966162 cites W1982603620 @default.
• W3147966162 cites W1985778833 @default.
• W3147966162 cites W1994772304 @default.
• W3147966162 cites W1995137358 @default.
• W3147966162 cites W1998203489 @default.
• W3147966162 cites W1998682097 @default.
• W3147966162 cites W2008319170 @default.
• W3147966162 cites W2016624677 @default.
• W3147966162 cites W2021341670 @default.
• W3147966162 cites W2027146979 @default.
• W3147966162 cites W2027244603 @default.
• W3147966162 cites W2032430075 @default.
• W3147966162 cites W2032995263 @default.
• W3147966162 cites W2050389860 @default.
• W3147966162 cites W2051549807 @default.
• W3147966162 cites W2052891178 @default.
• W3147966162 cites W2073405971 @default.
• W3147966162 cites W2085950149 @default.
• W3147966162 cites W2086620944 @default.
• W3147966162 cites W2087123678 @default.
• W3147966162 cites W2091530001 @default.
• W3147966162 cites W2097387056 @default.
• W3147966162 cites W2102049157 @default.
• W3147966162 cites W2102512718 @default.
• W3147966162 cites W2104135721 @default.
• W3147966162 cites W2106493454 @default.
• W3147966162 cites W2106804121 @default.
• W3147966162 cites W2109890799 @default.
• W3147966162 cites W2110065044 @default.
• W3147966162 cites W2114104545 @default.
• W3147966162 cites W2115366701 @default.
• W3147966162 cites W2117458176 @default.
• W3147966162 cites W2118019849 @default.
• W3147966162 cites W2126354094 @default.
• W3147966162 cites W2127150495 @default.
• W3147966162 cites W2128120736 @default.
• W3147966162 cites W2128445526 @default.
• W3147966162 cites W2132488282 @default.
• W3147966162 cites W2141545183 @default.
• W3147966162 cites W2142020978 @default.
• W3147966162 cites W2145411470 @default.
• W3147966162 cites W2146040216 @default.
• W3147966162 cites W2147832388 @default.
• W3147966162 cites W2148810289 @default.
• W3147966162 cites W2152586871 @default.
• W3147966162 cites W2154196978 @default.
• W3147966162 cites W2161683058 @default.
• W3147966162 cites W2166234939 @default.
• W3147966162 cites W2169456326 @default.
• W3147966162 cites W2171175432 @default.
• W3147966162 cites W2179438025 @default.
• W3147966162 cites W2187090435 @default.
• W3147966162 cites W2197124664 @default.
• W3147966162 cites W2253146128 @default.
• W3147966162 cites W2313441807 @default.
• W3147966162 cites W2314502206 @default.
• W3147966162 cites W2332292689 @default.
• W3147966162 cites W2402959660 @default.
• W3147966162 cites W2409383155 @default.
• W3147966162 cites W2436716005 @default.
• W3147966162 cites W2520632143 @default.
• W3147966162 cites W2568959080 @default.
• W3147966162 cites W2592811885 @default.
• W3147966162 cites W2612504410 @default.
• W3147966162 cites W2620995371 @default.
• W3147966162 cites W2736671164 @default.
• W3147966162 cites W2744121859 @default.
• W3147966162 cites W2745685376 @default.
• W3147966162 cites W2765831845 @default.
• W3147966162 cites W2767423581 @default.
• W3147966162 cites W2768887441 @default.
• W3147966162 cites W2794480084 @default.
• W3147966162 cites W2794839416 @default.
• W3147966162 cites W2809279418 @default.
• W3147966162 cites W2810630532 @default.
• W3147966162 cites W2884297297 @default.
• W3147966162 cites W2887886950 @default.

• next